Holding Our Breath for Inhale
Executive SummaryPulmonary delivery seems a narrow base on which to build a company; but Inhale is confident that through rigorous focus, it can construct plenty of deals on it. In the meantime, all eyes are on its insulin deal with Pfizer. That deal's success or failure--for reasons that may have nothing to do with Inhale or its technology--will either bring in partners still uncertain about the delivery system or scare them off.
You may also be interested in...
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.